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GRAFf-VERSUS-HOST disease (GVHD) and al-lograft rejection in human small bowel transplanta-
tion (SBT) are not yet fully described. These complications 
may prevent successful SBT. Immunohistochemical as 
well as histologic studies could be valuable to interpret 
these biologic processes. Therefore, in this study. we 
monitored the replacement of donors' lymphocytes by 
recipients' in the small bowel and the migration of donor 
lymphocytes in the peripheral circulation (PC). and char-
acterized the cell surface markers of the graft-infiltrating 
cell. endothelial cell. and epithelial cell using a variety of 
monoclonal antibodies (MAb). 
MATERIALS AND METHODS 
The subjects ofthis study were five SBT patients treated with FK 
506. One patient received the small bowel allograft alone. and the 
others received the liver and small bowel allografts from the same 
donor. Blood samples were collected daily for 60 days and 
lymphocytes were separated by the Ficoll gradient centrifugation. 
Serial biopsies of allografts were taken from the patients. The 
immunostaining was performed using the MAb against the mis-
matched HLAs between donor and recipient (One Lambda. Los 
Angeles, Calif): anti-CD3, CD4, CDS, aT, CDI9, macrophage, 
HLA-ABC, HLA-DR, and ICAM-I (Dako, Santa Barbara, Calif). 
RESULTS 
Clinical GVHD was not observed in our first five patients 
within 6 months. Replacement of donors' lymphocytes by 
recipients' in the small bowel was completed within 12 
weeks in all cases. The percentage of donor lymphocytes 
in PC revealed 9% to 12% at the peak; however, they 
disappeared at 54 days after SBT at the longest. 
CD3+DR+ cells increased significantly in the lamina 
propria and epithelial glands during the rejection. CD8+ 
cells were also predominant. and macrophage infiltration 
was significant. CDI9+ cells were not detected in lamina 
propria. In contrast. CD3 + cell increase was minimal in 
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lamina propria and epithelial glands during the nonrejec-
tion period. Partial T cells expressed DR antigen. The 
expression of HLA-DR in the epithelium and ICAM-l in 
small vessel and lamina propria was enhanced during both 
rejection and nonrejection episodes. 
DISCUSSION 
It was reported that GVHD was well-controlled in SBT in 
the rat I and bone marrow transplantation in humans2 
treated with FK 506. Although transitional donor lympho-
cytes were seen in PC. our patients did not develop clinical 
GVHD after SBT. These results suggest that. under ap-
propriate immunosuppression, the immunosurveillance 
system in the host could eliminate donor lymphocytes 
resulting in the absence of clinical GVHD. 
The main effector cells found during rejection in SBT 
patients seem to be macrophages and CD8+ lymphocytes. 
The expression ofHLA-DR and ICAM-l in the epithelium 
did not reflect the magnitude of rejection episodes. There-
fore, to characterize graft-infiltrating lymphocytes, partic-
ularly activated T lymphocytes and macrophages in con-
junction with cytokine monitoring,3 may be of great 
importance in understanding rejection after SBT. 
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